Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Measurement uncertainty as a tool for evaluating the ‘grey zone’ to reduce the false negatives in immunochemical screening of blood donors for infectious diseases
Portuguese Institute of Blood and Transplantation, Portugal.
RISE., SP – Sveriges Tekniska Forskningsinstitut, SP Kemi Material och Ytor, Kemi.
Linköping University, Sweden.
University of Wisconsin, US.
Vise andre og tillknytning
2016 (engelsk)Inngår i: Accreditation and Quality Assurance, ISSN 0949-1775, E-ISSN 1432-0517, Vol. 21, nr 1, s. 25-32Artikkel i tidsskrift (Fagfellevurdert) Published
Resurstyp
Text
Abstract [en]

The risk of misclassifying infected individuals as healthy constitutes a crucial challenge when screening blood donors by means of immunoassays. This risk is especially challenging when the numerical results are close to the clinical decision level, i.e. in the ‘grey zone’. The concept of using measurement uncertainty for evaluating the ‘grey zone’ has previously not been systematically applied in this context. This article explains methods, models and empirical (top-down) approaches for the calculation of measurement uncertainty using results from a blood bank according to the internationally accepted GUM principles, focusing on uncertainty sources in the analytical phase. Of the different approaches available, the intralaboratory empirical approaches are emphasised since modelling (bottom-up) approaches are impracticable due to the lack of reliable model equations for immunoassays. Different methods are applied to estimate the measurement uncertainty for the Abbott Prism® HCV immunoassay. The expanded uncertainty obtained at the clinical decision level from the intralaboratory empirical approach was 36 %. The estimated uncertainty was used to set acceptance and rejection zones following the procedure set in the Eurachem guideline, emphasising the need to minimise the occurrence of false negatives.

sted, utgiver, år, opplag, sider
Springer-Verlag New York, 2016. Vol. 21, nr 1, s. 25-32
Emneord [en]
blood bank, clinical decision level, cut-off value, GUM, immunoassay, measurement uncertainty, screening test, ‘grey zone’
HSV kategori
Identifikatorer
URN: urn:nbn:se:ri:diva-96DOI: 10.1007/s00769-015-1180-xScopus ID: 2-s2.0-84957938245OAI: oai:DiVA.org:ri-96DiVA, id: diva2:932132
Tilgjengelig fra: 2016-05-31 Laget: 2016-04-28 Sist oppdatert: 2020-12-01bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstScopus
Av organisasjonen
I samme tidsskrift
Accreditation and Quality Assurance

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 80 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
v. 2.43.0